Table 2.
Baseline Characteristics of High‐Risk Group by Warfarin Status (Before and After Matching)
| Before Matching | P Value | After Matching | P Value | Standardized Difference | |||
|---|---|---|---|---|---|---|---|
| Warfarin (n=252) | No Warfarin (n=184) | Warfarin (n=126) | No Warfarin (n=126) | ||||
| Age (y), mean (SD) | 58.5 (12.4) | 64.0 (14.8) | <0.001 | 61.9 (12.4) | 61.5 (14.3) | 0.81 | 0.03 |
| Female | 57 (22.6) | 52 (28.3) | 0.18 | 34 (27.0) | 29 (23.0) | 0.47 | 0.09 |
| GRACE risk score, median (IQR) | 163 (142, 189) | 181 (152, 213) | <0.001 | 167 (148, 197) | 169 (144, 199) | 0.56 | 0.06 |
| Creatinine (μmol/L), mean (SD) | 91.3 (24.4) | 102.2 (47.9) | 0.002 | 90.5 (25.6) | 95.1 (39.8) | 0.28 | −0.14 |
| Medical history | |||||||
| Hypertension | 111 (44.0) | 95 (51.6) | 0.12 | 61 (48.4) | 61 (48.4) | 0.99 | 0.00 |
| Diabetes mellitus | 47 (18.7) | 33 (17.9) | 0.85 | 25 (19.8) | 19 (15.1) | 0.32 | 0.13 |
| Dyslipidemia | 101 (40.1) | 77 (41.8) | 0.71 | 54 (42.9) | 51 (40.5) | 0.70 | 0.05 |
| Prior MI | 37 (14.7) | 37 (20.1) | 0.14 | 24 (19.0) | 22 (17.5) | 0.74 | 0.04 |
| Family history premature CAD | 46 (18.3) | 39 (21.2) | 0.44 | 22 (17.5) | 30 (23.8) | 0.21 | −0.16 |
| Symptom onset to first medical contact (min), median (IQR) | 120 (66, 400) | 169 (71, 593) | 0.25 | 140 (65, 567) | 157 (70, 398) | 0.87 | 0.10 |
| Reperfusion modality | |||||||
| Primary PCI | 138 (54.8) | 87 (47.3) | <0.001 | 63 (50.0) | 61 (48.4) | 0.96 | 0.03 |
| Fibrinolysis | 92 (36.5) | 55 (29.9) | 47 (37.3) | 48 (38.1) | … | … | |
| None | 22 (8.7) | 42 (22.8) | 16 (12.7) | 17 (13.5) | … | … | |
| Length of hospital stay (days), median (IQR) | 7 (5, 9) | 6 (4, 10) | 0.003 | 7 (5, 10) | 5 (4, 9) | 0.004 | −0.05 |
| In‐hospital medications | |||||||
| Dual anti‐platelet therapy | 245 (97.2) | 172 (93.5) | 0.059 | 119 (94.4) | 119 (94.4) | 0.99 | 0.00 |
| ACE‐I/ARB | 247 (98.0) | 165 (89.7) | <0.001 | 123 (97.6) | 124 (98.4) | 0.65 | −0.06 |
| β‐Blocker | 251 (99.6) | 174 (94.6) | <0.001 | 126 (100.0) | 125 (99.2) | 0.32 | 0.13 |
| Cholesterol lowering | 242 (96.0) | 172 (93.5) | 0.23 | 121 (96.0) | 122 (96.8) | 0.73 | −0.04 |
Numbers are n (%) unless specified otherwise; P values calculated by χ2 test (proportions), t test (means), or Wilcoxon‐Mann–Whitney test (medians). Matched groups exclude patients who died during index hospitalization and those with left ventricular thrombus. ACE‐I indicates angiotensin‐converting enzyme‐inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; GRACE, Global Registry of Acute Coronary Events; IQR, interquartile range; MI, myocardial infarction; PCI, percutaneous coronary intervention.